

Amendments to Claims:

Please enter the following amendments so that the claims read as follows.

1. (currently amended) A method for ~~controlling excessive~~ at least partially inhibiting proliferation or migration of smooth muscle cells in vitro comprising treating said smooth muscle cells with an effective amount of an antibody antagonist of a native ErbB4 receptor of SEQ ID NO.: 2.

2. (currently amended) The method of claim 1 wherein ~~the control is~~ at least partially inhibiting comprises prevention of excessive proliferation or migration of smooth muscle cells.

3. (currently amended) The method of claim 1 wherein ~~the control is~~ at least partially inhibiting comprises inhibition of excessive proliferation or migration of smooth muscle cells.

4. (canceled)

5. (original) The method of claim 1 wherein said smooth muscle cells are pyloric smooth muscle cells.

6. (original) The method of claim 1 wherein said smooth muscle cells are urinary bladder smooth muscle cells.

7. (original) The method of claim 1 wherein said smooth muscle cells are those of an airway passage.

8. (canceled)

9. (original) The method of claim 1 wherein said smooth muscle cells are vascular smooth muscle cells.

10. (original) The method of claim 9 wherein said vascular smooth muscle cells are human.

11. (original) The method of claim 9 wherein said vascular smooth muscle cells are human aortic smooth muscle cells.

12-22. (canceled)

23. (previously amended) The method of claim 1 wherein said antibody is a neutralizing antibody against a native ErbB4 receptor of SEQ ID NO.: 2.

24. (original) The method of claim 23 wherein said antibody is a chimeric, humanized or human antibody.

25. (original) The method of claim 23 wherein said antibody is glycosylated.

26. (original) The method of claim 23 wherein said antibody binds essentially the same epitope as an antibody produced by a hybridoma selected from the group consisting of HER4.10H1.1A1 (ATCC Accession Number PTA-2828), HER4.1C6.A11 (ATCC Accession Number PTA-2829), HER4.3B9.2C9 (ATCC Accession Number PTA-2826), HER4.1A6.5B3 (ATCC Accession Number PTA-2827) and HER4.8B1.2H2 (ATCC Accession Number PTA-2825).

27. (original) The method of claim 23 wherein said antibody has complementarity determining region (CDR) residues from an antibody produced by a hybridoma selected from the group consisting of HER4.10H1.1A1 (ATCC Accession Number PTA-2828), HER4.1C6.A11 (ATCC Accession Number PTA-2829), HER4.3B9.2C9 (ATCC Accession Number PTA-2826), HER4.1A6.5B3 (ATCC Accession Number PTA-2827) and HER4.8B1.2H2 (ATCC Accession Number PTA-2825).

28-84. (canceled)